Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Vyant Bio, Inc. | a17-29002_1ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 28, 2017
CANCER GENETICS, INC.
(Exact Name of Registrant as Specified in its Charter)
|
Delaware |
|
001-35817 |
|
04-3462475 |
|
(State or Other |
|
(Commission |
|
(IRS Employer |
|
Jurisdiction of |
|
File Number) |
|
Identification No.) |
|
Incorporation) |
|
|
|
|
201 Route 17 North 2nd Floor, Rutherford, New Jersey 07070
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code (201) 528-9200
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Item 8.01. Other Events
On December 28, 2017, Cancer Genetics, Inc. issued a press release announcing its receipt of approximately $1,100,000 with respect to the New Jersey Technology Business Tax Certificate Transfer (NOL) Program.
Item 9.01. Financial Statements and Exhibits.
|
(d) |
Exhibit No. |
|
Description |
|
|
|
|
|
|
|
99.1 |
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
CANCER GENETICS, INC. | ||
|
|
| ||
|
|
By: |
/s/John A. Roberts | |
|
|
|
Name: |
John A. Roberts |
|
|
|
Title: |
Chief Operating Officer |
Date: December 28, 2017